For example, the range of reported AGR2‐positive cases ranged from 56.8% to 100% in adenocarcinoma of the lung [10, 24], from 57.0% to 95.4% in prostate cancer [21, 23], and from 19.0% to 46.1% in serous carcinoma of the ovary [13, 25]. The gene discussed is AGR2; the disease is lung adenocarcinoma.